Sort
10,766 grants matching “checkpoint inhibitor”
Project 1: Priming and propagating immunity against head and neck cancer using targeted radionuclide therapy
$347,511Zachary Scott Morris · University Of Wisconsin-Madison · P50 · FY2025 · CA
Novel NEK2 signaling pathways in myeloma progression
$347,510Fenghuang Zhan · Univ Of Arkansas For Med Scis · R01 · FY2020 · CA
Development of a targeted delivery platform for checkpoint inhibitors
$347,471Kun Cheng · University Of Missouri Kansas City · R01 · FY2022 · CA
Effect of DNA repeat silencing on efficacy of ATRi in prostate cancer treatment
$347,378Eric J Brown · University Of Pennsylvania · R01 · FY2025 · CA
Optimizing systemic immunotherapy for personalized brain metastasis treatment
$347,313Michael Lim · Stanford University · U54 · FY2023 · CA
Project 3: Maximizing Anti-tumor Activity through Simultaneous Activation of the Innate and Adaptive Immune System in Kidney Cancer
$347,134Raquibul Hannan · Ut Southwestern Medical Center · P50 · FY2024 · CA
Selective Sensitization of Pancreatic Cancer to Therapy by Chk1 and PARP1 Inhibit
$347,032Meredith A Morgan · University Of Michigan At Ann Arbor · R01 · FY2015 · CA
Project 3: Targeting Bax signaling to overcome treatment resistance in NSCLC
$347,015Xingming Deng · Emory University · P50 · FY2020 · CA
Molecular Mechanisms of Replication Stress Response
$347,014Huzefa Mannan Dungrawala · University Of South Florida · R35 · FY2020 · GM
Converting Cold to Hot Tumor Microenvironment in Prostate Cancer by Targeting Chromatin Effector
$346,934Xin Lu · University Of Notre Dame · R01 · FY2023 · CA
Robust-to-fragile transitions of a phase-separated mitotic organelle in triple-negative breast cancer
$346,810P. Todd Stukenberg · University Of Virginia · U54 · FY2024 · CA
Project 4: Combined targeting of DNA repair and macrophage-mediated immunosuppression in BRCA1/2-associated breast cancer
$346,781Geoffrey I Shapiro · Dana-Farber Cancer Inst · P50 · FY2025 · CA
Project 2: Androgen deprivation as an immune modulating therapy in combination with targeted immunotherapy of prostate cancer
$346,701Douglas G McNeel · University Of Wisconsin-Madison · P50 · FY2023 · CA
Colorectal carcinogenesis and Fusobacterium nucleatum: oncomicrobe, oncometabolites, and oncoimmunology
$346,690Wendy S. Garrett · Harvard School Of Public Health · R01 · FY2017 · CA
Colorectal carcinogenesis and Fusobacterium nucleatum: oncomicrobe, oncometabolites, and oncoimmunology
$346,690Wendy S. Garrett · Harvard School Of Public Health · R01 · FY2021 · CA
Colorectal carcinogenesis and Fusobacterium nucleatum: oncomicrobe, oncometabolites, and oncoimmunology
$346,690Wendy S. Garrett · Harvard School Of Public Health · R01 · FY2020 · CA
Project 2: Targeting Neoantigens for Lung Cancer Immunotherapy
$346,635Stanley R Riddell · Fred Hutchinson Cancer Center · P50 · FY2023 · CA
Project 2: Targeting Neoantigens for Lung Cancer Immunotherapy
$346,635Stanley R Riddell · Fred Hutchinson Cancer Center · P50 · FY2022 · CA
Project 2: Targeting Neoantigens for Lung Cancer Immunotherapy
$346,634Stanley R Riddell · Fred Hutchinson Cancer Research Center · P50 · FY2019 · CA
Project 1: Personalized Adjuvant Immunotherapy for High-risk Colorectal Cancer.
$346,624Patrick Hwu · University Of Tx Md Anderson Can Ctr · P50 · FY2019 · CA
Polo-Like Kinase 1 as a Therapeutic Target in Medulloblastoma
$346,576Rajeev Vibhakar · University Of Colorado Denver · R01 · FY2016 · NS
Polo-Like Kinase 1 as a Therapeutic Target in Medulloblastoma
$346,576Rajeev Vibhakar · University Of Colorado Denver · R01 · FY2015 · NS
Polo-Like Kinase 1 as a Therapeutic Target in Medulloblastoma
$346,576Rajeev Vibhakar · University Of Colorado Denver · R01 · FY2017 · NS
USC-UCLA Drug-Induced Liver Injury (DILI) Clinical Center
$346,560Andrew Abba Stolz · University Of Southern California · U01 · FY2024 · DK
Expanding the Therapeutic Window of Nanoparticle STING Agonists for Cancer Immunotherapy
$346,493John Tanner Wilson · Vanderbilt University · R01 · FY2024 · CA